Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

Eli Lilly and Company and Boehringer Ingelheim announce regulatory submission for new insulin glargine biosimilar product

Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news